Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

n innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the IDEAL study and the potential market for PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item 1A. "Risk Factors" in Schering-Plough's 2007 10-K/A.

Endnotes:

1 Pegasys and Copegus are registered trademarks of Hoffmann-La Roche Inc.

Please see the Pegasys and Copegus product inserts for information on

these products.'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Texas , March 3, 2015  UnaliWear announces ... provides advanced support for seniors that guards against wandering ... The new wearable – the Kanega watch ... its kind to use an easy speech interface rather ... medical information without human input. The ...
(Date:3/3/2015)... -- American Biosurgical, LLC ("ABI") ( www.americanbiosurgical.com ) a ... in the design, development and production of innovative ... device companies has announced the acquisition of MTI ... cable manufacturer based in North Carolina.  The new ... name MTI Medical Cables.  The ...
(Date:3/3/2015)... Ariz. , March 3, 2015  Michigan brothers ... heart condition called arrhythmogenic right ventricular dysplasia, or ARVD, a ... cause of sudden death among young athletes. In ... at a basketball game. They later tested Dominique and found ... to a February 19, 2015 story in The Ann ...
Breaking Medicine Technology:UnaliWear's Wearable For Seniors Extends Independence With Advanced Technology 2American Biosurgical Acquires MTI Corporation 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 3
(Date:3/4/2015)... Follow us on LinkedIn ... worldwide. The rising prevalence of high blood pressure in ... both developed and developing countries. By 2025, the number ... 1.5 billion, equating to approximately 30% of the total ... to come from the developing countries. Major lifestyle factors ...
(Date:3/4/2015)... March 04, 2015 Developers of FCPX ... a new overlay plugin for Final Cut Pro X entitled ... Overlays Lens Dirt gives users total control over 6k lens ... CEO of Pixel Film Studios. “FCPX Overlays Lens Dirt was ... easy to use interface.” , FCPX Overlays Lens Dirt from ...
(Date:3/4/2015)... March 04, 2015 The medical device ... whose management forgot – or ignored or didn't know ... the market based on physician input before proceeding to ... more specifically, founders – become so enamored of an ... question: Will physicians use the device?” says Dr. ...
(Date:3/3/2015)... On February 24, 2015, a Toledo, Ohio ... District Court for the Northern District of Ohio against ... insurance companies Balboa, QBE, and Newport Management. (See Amended ... , The Plaintiff, a Ms. Dolores Gorsuch, says her ... to buy too much insurance at rates that were ...
(Date:3/3/2015)... March 03, 2015 Longtime parent visionary ... CARE Surrogacy Center for a candid interview ... appearing online is an exhilarating revelation of his magical ... led him from Australia to the birth of his ... interchange, Tolga Umar, CEO and Founder of CARE stated, ...
Breaking Medicine News(10 mins):Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 2Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 3Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 4Health News:Pixel Film Studios released a New Overlay Plugin entitled FCPX Overlays Lens Dirt Exclusively for Final Cut Pro X users 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 3
... HealthDay Reporter , THURSDAY, Dec. 9 (HealthDay News) ... potentially promising weapon against breast cancer recurrence, has flopped ... Zometa did not appear to prevent breast cancer ... researchers presented the disappointing findings Thursday at the San ...
... A new study challenges the theory that lowering the minimum ... binge drinking by college students. Some college presidents and ... bars and restaurants, they might learn more moderate drinking habits, ... college campuses. The idea is being promoted through an effort ...
... Ewa Kuligowska-Noble, MD, FACR, a radiologist at Boston ... Boston University School of Medicine (BUSM), is the recipient ... Association for Women Radiologists. The award, which is presented ... contribution to the field of radiology, was given to ...
... demands on a couple seeking fertility treatment can be daunting. ... fertility to increase a couple,s chances of becoming pregnant in ... Infants Hospital is one of the centers participating in a ... fertility drug. This new drug would require one weekly ...
... By Kathleen Doheny HealthDay Reporter , THURSDAY, ... to counter the prevailing wisdom that any form of hormone ... look at some old data suggests that estrogen-only hormone therapy ... disease. "Exogenous estrogen [such as hormone therapy] is actually ...
... have argued that lowering the minimum legal drinking age could help ... issue of the Journal of Studies on Alcohol and Drugs ... In 2008, a group of college presidents and ... minimum legal drinking age of 21. They argue that the law ...
Cached Medicine News:Health News:Bone Drug Zometa Flops Overall as Breast Cancer Treatment 2Health News:Bone Drug Zometa Flops Overall as Breast Cancer Treatment 3Health News:BMC radiologist receives 2010 Marie Sklodowska-Curie Award from AAWR 2Health News:Estrogen-Only Hormone Therapy May Reduce Breast Cancer Risk for Some 2Health News:Estrogen-Only Hormone Therapy May Reduce Breast Cancer Risk for Some 3Health News:Lowering the drinking age is unlikely to curb college binge drinking 2
Ideal for abdominal procedures...
... in the abdominal area for the taller, ... and eye closures extend the full,length of ... very thin zipper opens the garment completely. ... gripper lace trim, and adjustable detachable straps ...
For lipoplasty of trochanteric region, abdomen, thighs, hips/flanks, buttocks & knees...
White Standard Girdle...
Medicine Products: